By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Teva Pharmaceutical Industries Limited 

5 Basel Street

Petach Tikva    49131  Israel
Phone: 972-3-9267-267 Fax: 972-3-9234-050


Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.




Founders: Chaim Salomon, Moshe Levin, and Yitschak Elstein

CEO: Erez Vigodman

CEO Global Operations: Carlo de Notaristefani

CEO Global Specialty Medicines: Rob Koremans

CEO Global Generic Medicines: Sigudur (Siggi) Olafsson

CFO: Eyal Desheh

CMO (Medical):

CSO (Scientific): Michael Hayden


Please click here for Teva Pharma job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Teva
Employees: 5,700
Symbol: TEVA


Company News
AstraZeneca PLC (AZN) CEO Breaks Silence on Teva (TEVA) Rumors, Urges Staff to Remain Focused in Leaked Memo 7/21/2017 5:37:40 AM
Teva (TEVA) Release: NICE Recommends CINQAERO (Reslizumab) For The Treatment Of Severe Eosinophilic Asthma 7/20/2017 11:01:11 AM
European Commission (EC) Accuses Teva (TEVA), Cephalon (CEPH) of Anti-Competitive Behavior 7/17/2017 6:04:08 AM
Teva (TEVA) Enhances Board Of Directors As All Proposals Approved At Annual General Meeting Of Shareholders 7/13/2017 11:12:37 AM
Rumor Alert: AstraZeneca PLC (AZN) CEO to Become Teva (TEVA)'s New Leader 7/12/2017 4:41:50 PM
Teva (TEVA) Accuses Former Top Exec of Passing on Trade Secrets to Boyfriend—CEO of Rival Apotex 7/12/2017 6:35:02 AM
Teva (TEVA) And The Huntington Study Group Announce Publication Of Data For AUSTEDO (Deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology 7/11/2017 9:07:35 AM
Teva (TEVA) To Report Second Quarter 2017 Financial Results On August 3, 2017 7/11/2017 9:01:25 AM
Teva (TEVA) Announces Publication Of AIM-TD Study Results In The Lancet Psychiatry For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 6/29/2017 9:56:12 AM
Celltrion And Teva (TEVA) Announce U.S. FDA Acceptance Of Biologics License Application For Proposed Biosimilar To Rituxan (Rituximab) 6/29/2017 9:33:11 AM